ClinicalTrials.Veeva

Menu

Levita Magnetic Grasper Device Safety and Performance Study

L

Levita Magnetics

Status

Completed

Conditions

Benign Gallbladder Disease

Treatments

Device: Use of Levita Magnetics Grasper

Study type

Interventional

Funder types

Industry

Identifiers

NCT02049983
LEV-TP-0010
Grant 13IEAT-20911 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to determine the Levita Magnetic Grasper Device Safety and Performance in Laparoscopy.

Enrollment

50 patients

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient is between 18 and 60 years of age

    • Undergoing elective cholecystectomy due to:
    • Cholelithiasis (Gallbladder stones < 2.5cm in longer measurement (length or width))
    • Gallbladder polyps as assessed by ultrasound
    • Absence of non-correctable coagulopathy (INR < 1.4 or, platelet count of < 50,000/mcl)
    • Patient has a body mass index (BMI) ≤ 35 kg/m2 and over 20
    • Patient, or authorized representative, signs a written Informed Consent form to participate in the study, prior to any study mandated determinations or procedure

Exclusion criteria

  • Emergency presentation with acute gallbladder disease

    • Pancreatitis
    • Jaundice
    • Scleroatrophic gallbladder as shown by ultrasound
    • Biliary tract stones diagnosed before or during surgery
    • Acute cholecystitis
    • Gallbladder Empyema
    • Ongoing peritoneal dialysis
    • Previous abdominal surgery or laparotomy (presence of any previous upper umbilical incision)
    • Presence of umbilical hernia or previous umbilical hernia
    • American Society of Anesthesiologists (ASA) score of III or IV
    • Patient is undergoing treatment for chronic pain of any origin
    • Significant comorbidities: cardiovascular, neuromuscular, chronic obstructive pulmonary disease, and urological disease (renal failure)
    • Patients with signs of gallbladder perforation diagnosed by ultrasound
    • Suspicion of biliary cancer
    • Patients with severe peritonitis
    • Contraindications to pneumoperitoneum
    • Known allergy to paracetamol or NSAIDs
    • Patients with metallic implants (such as pacemakers, prosthesis, etc)
    • Previously diagnosed or suspected of having a history of choledocholithiasis based on any alterations in plasma hepatic enzymes
    • Has a biliary tract > 7mm in size as determined by ultrasound
    • Has a gallbladder wall thickness that is > 5mm
    • Diabetic Blood coagulation issues
    • Has signs of hepatic endocrinology (i.e: cirrhosis, liver failure, increase in liver enzymes, etc.)
    • History of endoscopic papillotomy (i.e: Preoperative indication of endoscopic retrograde cholangiopancreatography (ERCP)
    • Patient is pregnant or wishes to become pregnant during the length of study participation or lactation
    • Patient is not likely to comply with the follow-up evaluation schedule
    • Patient is participating in a clinical trial of another investigational drug or device
    • Patient is mentally incompetent or a prisoner
    • Known or suspected drug or alcohol abuse
    • Patient has systemic infection or evidence of any surgical site infection (superficial or organ space)
    • Patient has compromised immune system or autoimmune disease (WBC < 4000 or > 20,000), including prior or pending treatment for HIV or Hep. C
    • Patient intra-operatively needs an additional surgery while undergoing elective cholecystectomy

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

50 participants in 1 patient group

Use of Levita Magnetics Grasper
Experimental group
Treatment:
Device: Use of Levita Magnetics Grasper

Trial contacts and locations

3

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems